With 17 years' experience, Mabion offers an “end-to-end” solution, covering all stages of biologic drug development, from early clone selection and small-scale manufacturing through process ...

They will also apprehend the manufacturing and scale up challenges, looking at compatibility problems, lyophilisation issues, and consider the different possibilities offered for drug delivery ...

A PAT roadmap should address data analysis, aggregation, visualization, and the smart utility of those data for greater process understanding.

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...

In response to the growing demand for peptide drugs, Cytovance Biologics and PolyPeptide ... in microbial and mammalian expression, process development and cGMP manufacturing with PolyPeptide ...

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart ...

WuXi Biologics differentiates itself from ... Pre-IND includes drug discovery and preclinical development. At that time we did not believe its pre-IND business had a moat. Now late-phase services ...

“This collaboration with Samsung Biologics will be an important step toward strengthening the supply chain of high-quality ADC drugs and enhancing the competitiveness ... in large-scale antibody ...